SCHEMBL5137873

SCHEMBL5137873

CCCCN(Cc1c(F)cccc1F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.38
C5AR1 P21730 1/20 0.38
CRHR1 P34998 3/20 0.37
TSHR P16473 6/20 0.37
ALDH1A1 P00352 6/20 0.37
HPGD P15428 6/20 0.37
HSD17B10 Q99714 6/20 0.37
CYP3A4 P08684 5/20 0.37
HDAC1 Q13547 1/20 0.36
ATP4A P20648 2/20 0.35
ATP4B P51164 2/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2A P29274 1/20 0.35
ADORA2B P29275 1/20 0.35
ADORA1 P30542 1/20 0.35
NR1H3 Q13133 1/20 0.34
CYP2C9 P11712 1/20 0.34
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5074878 0.96 TSHR (0.42) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5134701 0.95 KDM4E (0.39) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5072419 0.93 CRHR1 (0.36) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5135270 0.93 KDM4E (0.39) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5135648 0.92 CRHR1 (0.38) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5135911 0.92 TSHR (0.39) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5134981 0.92 C5AR1 (0.36) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5135045 0.90 C5AR1 (0.38) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5137572 0.90 C5AR1 (0.39) KDM4EC5AR1CRHR1TSHRALDH1A1
SCHEMBL5136644 0.89 KDM4E (0.40) KDM4EC5AR1CRHR1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed